Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19
NCT ID: NCT04344080
Last Updated: 2022-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2020-04-01
2021-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adjuvant Therapy With CytoSorb in Refractory Septic Shock
NCT04013269
Registry of CytoSorb Therapy in COVID-19 ICU Patients
NCT04391920
Prospective Study for the Application of Cytosorb® in Critically Ill Patients
NCT04913298
Cytokine Adsorption in Severe, Refractory Septic Shock
NCT04910893
Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis
NCT00559130
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CytoSorb-Therapy
Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care in Addition with hemoadsorption using CytoSorb-Adsorber
CytoSorb-Therapy
Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
Standard of care
Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CytoSorb-Therapy
Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg
* IL6 ≥ 500 ng/l
* Indication for CRRT or ECMO
Exclusion Criteria
* "do not resuscitate"-order
* expected survival due to comorbidities \< 14 days
* pregnancy or breastfeeding
* participation in another interventional trial
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitätsklinikum Hamburg-Eppendorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefan Kluge, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Hamburg-Eppendorf, Department of Intensive Care Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Hamburg-Eppendorf
Hamburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Published trial on PubMed.gov
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1250-2078
Identifier Type: REGISTRY
Identifier Source: secondary_id
DRKS00021199
Identifier Type: REGISTRY
Identifier Source: secondary_id
CYTOCOV-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.